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Abstract – Ki-67 expression is strongly correlated with tumour cell proliferation and growth. It is 
widely used as a proliferation marker in the routine pathological investigation. The nuclear protein Ki-
67 (pKi67) is recognised prognostic and predictive indicator for the biopsies assessment for cancer 
patients. Clinically, pKi67 has been revealed to associate with metastasis and the clinical stage of 
tumours. Furthermore, it has been presented that the expression of Ki-67 is significantly higher in 
malignant tissues with poorly differentiated tumour cells, as compared with normal tissue. The Ki-67 
labelling index plays a vital role as an independent prognostic factor for survival rate, which includes 
all stages and grade categories. There is an association between the ratios of Ki-67 positive malignant 
cells and patient survival. This review provides an overview of recent advances in detecting Ki-67 in 
ovarian carcinoma. 
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Introduction  
Ovarian carcinoma has been known as the third most common gynaecological malignancy worldwide 
with approximately 239 000 new cases been reported every year (Ferlay, 2012). This malignancy 
signifies the fourth most frequently diagnosed among Malaysian women (Zainal & Nor Saleha, 2011). 
Epithelial ovarian cancer accounts for 90% of all ovarian cancer, and it comprises of the serous, 
endometrioid, mucinous and clear cell, with serous being the most common among all (Bast, 2009; Ng., 
2012). The high mortality of this tumor is principally explained by the fact that the majority which is 
approximately about 75 % of patients present at an advanced stage (stage III and IV), with extensively 
metastatic disease within the peritoneal cavity (Lengyel, 2012). Efforts at the early discovery and new 
therapeutic approaches to lessen death have been mainly ineffective owing to the absence of ultimate 
etiological factors and diagnostic assistances for screening. Numerous factors, for instance, age, race, 
histologic type, grade, Federation of Gynecology and Obstetrics (FIGO) stage, residual disease, CA125 
levels and performance status at the time of diagnosis may affect the survival of Surface Epithelial 
Ovarian Carcinoma (SEOC). These factors are unsuccessful to elucidate the biological behaviour of 
ovarian cancer, and therefore, new objective ways to establish the prognosis are required (Kurman et 
al., 2010; Liu et al., 2012; Heeran et al., 2013; Ezzati et al., 2014). Cell division has a significant role 
in the clinical behaviour and aggressiveness of ovarian carcinoma. Many studies have been performed 
and concluded that the determination of the proliferative activity of tumor cells would help in diagnostic 
and prognostic. Thus, various techniques are used to evaluate the number of proliferating cells (Heeran 
et al., 2013; Ezzati et al., 2014; Mita et al., 2004; Gursan et al., 2009, Mahadevappa et al., 2017). The 
Ki-67 antigen was originally identified by Scholzer and Gerdes in the early 1980s. It has molecular 
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weights of 345 and 395 kDa and encodes two protein isoforms (Scholzen & Gerdes, 2009). The Ki-67 
protein (pKi67) has a half-life of only ~1-1.5 h. It is present during all active phases of the cell cycle 
including G1, S, G2 and M. However; it is absent in resting cells (G0) (Shirendeb et al., 2009; Hooghe 
et al., 2008 ). In anaphase and telophase, a sharp decrease in Ki-67 levels occurs (Modlin et al., 2008). 
This protein can be used as a marker of tumor aggressiveness due to its expression that is associated 
with the proliferative activity of intrinsic cell populations in malignant tumors (Klöppel et al., 2004; 
Brown & Gatter, 2004). The prognostic value of pKi67 has been investigated in a number of studies 
with its potential as a reliable marker having been shown in cancers other than ovarian such as breast, 
soft tissue, lung, prostate, cervix and central nervous system (18-22 Ishihara et al., 2013; Sorbye et al., 
2012; Ciancio et al., 2012; Josefsson et al., 2012). Plenty of studies have demonstrated that Ki-67 
immunohistochemical (IHC) staining is an effective technique to assess the prognosis in a numerous 
cancers type. Hence, existing classification schemes may require revision where biological behavior 
and prognostic implication of these tumors is concerned, as an increasing number of studies have 
recommended that Ki-67 may be an important factor in cancer grading and prognostic evaluation 
(Iatropoulos et al., 1996; Jacquemier et al., 1998). This review provides an update on the current 
knowledge of Ki-67 and the evidence regarding the prognostic role of this marker. 
 
Ki-67 in Ovarian Carcinoma  
It is acknowledged that Ki-67 is expressed in all cell-cycle phases but is absent in the resting phase cell, 
G0. Researchers suggest its use as a prognostic marker over mitotic rate (Petit et al., 2004; Chang et al., 
2000; Viale et al., 2008; Yerushalmi et al., 2010). Numerous studies have similarly confirmed the 
finding of Harlozinska et al. (1995) that growth fraction as measured by Ki-67 staining was significantly 
higher in stages III and IV, compared to stages I and II of ovarian carcinomas (Hartozinska et al., 1995). 
Kaern and his colleagues (2005) reported that on multivariate analysis, the high Ki-67 score was one of 
the important prognosis factors in a patient with stage III ovarian cancer (Kaern et al., 2005). This 
finding also has supported by Khouja et al. (2007) in which the study found that Ki-67 represents an 
independent prognostic predictor in stage III ovarian cancer (Khouja et al., 2007). Other study done by 
Min et al. (2007) disclosed that p53 and Ki-67 overexpression (> 50 %) were absent in the borderline 
ovarian tumors (32). Other studies that presented the same outcome also reported by Choudhury et al. 
(2011) and Giurgea et al. (2012) where they found that nuclear Ki-67 immunoexpression was more 
obvious in advanced stage tumors and malignant tumors compared to benign and borderline tumors, 
respectively (Choudhury et al., 2011; Giurgea et al., 2012).  
 
In another perspective, Harlozinska et al. (1995) demonstrated that the increased proliferative activity 
of cells seems to involve immunohistochemically detectable alterations in p53 gene contributing to the 
evolution of ovarian carcinoma (Yerushalmi et al., 2010). In addition, other study done by Garzetti and 
his colleagues (1995) showed that the proliferation index detected by Ki-67 antigen immunostaining 
might represent an indicator of aggressiveness in serous ovarian tumors and useful independent 
prognostic factor (Garzetti et al., 1995). Furthermore, Min et al. (2007) reported that p53 and Ki-67 
expression might be used as markers to predict aggressive behavior and to differentiate between 
malignant and borderline epithelial ovarian tumors (Min et al., 2007 ). Moreover, Liu and his colleagues 
(2011) investigated and presented that the CD105 and Ki-67 expressions might be involved in the 
progression of epithelial ovarian cancer (EOC) and patient prognosis (Liu et al., 2012). These outcomes 
have supported by a study by Choudhury and his colleagues (2011), where they reported that higher Ki-
67 index points toward the aggressive behavior and poorer clinical outcomes (Choudhury et al., 2011). 
Other study constructed by Aune et al. (2011) found that the proliferation markers Ki-67/MIB-1, PHH3, 
and survivin are positively correlated with each other and with tumor grade, and may contribute in the 
identification of aggressive ovarian carcinomas (Aune et al., 2011). In other study done by Marinas and 
her colleagues (2012), they demonstrated that EGFR, HER2/neu and Ki-67 could be used to identify 
benign/borderline tumors with progression potential and the aggressive malignant tumors (Marinas et 
al., 2012). However, Giurgea et al. (2012) found that the low Ki-67 immunoreaction in borderline 
tumors suggests that increased expression occurs later in the development of carcinoma (Giurgea et al., 
2012).  
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Ki-67 Immunostaining  
Ki-67 antigen immunostaining also may play a role as a prognostic indicator. Many studies have been 
done for example; Garzetti and his colleagues (1995) reported that proliferation index detected by Ki-
67 antigen immunostaining might represent as a useful prognostic factor in cystoadenocarcinomas, 
probably independent of and more significant than the architectural tumor grade and the disease FIGO 
stage (Garzetti et al., 1995). Besides, Viale et al. (1997) concluded that the simultaneous evaluation of 
p53 accumulation and MIB1 labelling index has independent prognostic implications in common 
epithelial malignancies of the ovary, irrespective of the disease stage (38). Other study performed by 
Liu et al. (2011) investigated and suggested a combined detection of  
 
CD105/Ki-67 coexpression may benefit us in predicting the prognosis in EOC (Liu et al., 2012). In 
addition, many studies were succeeded to correlate the high Ki-67 staining with poor outcome and 
patient survival. For instance, Mita et al. (2004) reported that the patients with higher proliferating 
tumors had a statistically significantly worse prognosis compared with those with lower proliferating 
tumors (p < 0.001) whereas a study performed by Kritpracha et al. (2005) concluded that levels of MIB-
1 staining above the cut-off point of 7.6 % had significantly poorer survival (10,39 ). Additionally, 
Khouja and his colleagues (2007) in a study to investigate the clinical importance of Ki-67, p16, p14 
and p57 expression in patients with advanced ovarian carcinoma found that in univariate analysis, high 
expression of Ki-67 (p = 0.0001) was associated with poor survival. However, in multivariate analysis, 
only high expression of Ki-67 was significantly associated with shorter survival in which the p value 
was 0.025 (Khouja et al., 2007). Other study performed by Gursan et al. (2009) demonstrated that 
multivariate analysis revealed a significant relationship between high Ki-67 immunostaining in ovarian 
neoplasms and disease-free survival and also indicated that high proliferation was associated with poor 
prognosis for ovarian cancer in both univariate and multivariate analyses (Gursan et al., 2009). This 
finding also supported by a study done by Heeran et al. (2012) in which they suggested that an increased 
level of MIB-1 (Ki-67) expression in tumour tissue, points to a less favourable outcome for ovarian 
cancer patients (Heeran et al., 2013). Furthermore, Sylvia et al. (2012) showed that higher Ki-67 in 
ovarian epithelial tumors with adverse prognostic factors would help in prognostication and 
differentiation (Sylvia et al., 2012). In other study constructed by Itamochi et al. (2002), found that the 
5-year survival rate for patients with clear cell carcinoma was significantly poorer, compared with 
serous adenocarcinoma (20.0 % versus 31.9 %). This study also concluded that lower proliferation of 
tumor might be a behavior of clear cell carcinoma of the ovary that contributes to its resistance to 
chemotherapy (Itamochi et al., 2002). However, in the other study performed by Khandakar et al. (2014), 
they concluded that Ki-67 expression was significantly lower in cases treated with neoadjuvant 
chemotherapy (NACT) and the survival outcome was significantly better in cases with low Ki-67 
(Khandakar et al., 2014). 
 
Indeed among the findings, many studies reported that high Ki-67 staining was found in serous type 
ovarian carcinoma. Rohlke et al. (1997) demonstrated that with respect to all tumors, high Ki-67 scores 
significantly more prevalent in serous-papillary types, carcinomas with high grade and moderate/high 
p53 expression (Röhlke et al., 1997). Moreover, Kritpracha et al. (2005) investigated and found that 
among patients with advanced epithelial ovarian carcinoma, MIB-1 immunostaining was higher in 
serous than in other histologic types (Kritpracha et al., 2005). Besides, Itamochi et al. (2002) constructed 
a study and concluded multivariable analysis revealed that Ki-67 labeling index (LI) in serous 
adenocarcinoma was significantly high (38.8 %) and was the independent prognostic factor (Itamochi 
et al., 2002).  
 
Conclusion 
Ki-67 is strongly correlated with cell proliferation and is widely used in routine pathology owing to its 
ability as a proliferation marker to measure the growth fraction of cells in human tumors. The expression 
of pKi67 is well characterised at the molecular level and thus extensively used as a prognostic marker 
in cancer. Based on the studies presented here, Ki-67 may be a promising molecular candidate for the 
diagnosis of a wide range of malignancies. However, its full potential in increasing proliferation has not 
been evaluated. In syngeneic animal models with subcutaneous or orthotopic bladder cancer, renal cell 
carcinoma or prostate cancer, antisense oligonucleotides stimulated tumor growth inhibition (Kausch et 
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al., 2003; Lu et al., 2012), potentially via the inhibition of Ki-67, demonstrating the participation of Ki-
67 in tumor cell proliferation. In other study constructed by Munstedt and his colleagues, they reported 
that Ki-67 expected tumor relapses in 84 % of the cases in the very early stages of ovarian carcinomas 
in which the p value was less than 0.001. This study suggested that Ki-67 as an additional tool in order 
to decide the adjuvant therapy for very early stages of ovarian carcinomas yet should be verified in 
prospective trials (Munstedt et al., 2004). In SEOC, histological grade and FIGO stages when combined 
with Ki-67 labeling index (LI) in histopathology report may help in diagnostic differentiation of 
subtypes, prognostication, deciding the need for adjuvant chemotherapy and in predicting survival 
analysis (Mahadevappa et al., 2011). 
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